Contrasting Aditxt (NASDAQ:ADTX) & Innate Pharma (OTCMKTS:IPHYF)

Innate Pharma (OTCMKTS:IPHYF) and Aditxt (NASDAQ:ADTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation.

Risk & Volatility

Innate Pharma has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, Aditxt has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500.

Valuation & Earnings

This table compares Innate Pharma and Aditxt”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$10.19 million	12.34	-$55.64 million	N/A	N/A
Aditxt	N/A	N/A	-$41.71 million	($11,103.38)	0.00

Aditxt has lower revenue, but higher earnings than Innate Pharma.

Analyst Recommendations

This is a summary of recent ratings and price targets for Innate Pharma and Aditxt, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	0	0	0	0	0.00
Aditxt	1	0	0	0	1.00

Insider & Institutional Ownership

15.5% of Aditxt shares are owned by institutional investors. 31.9% of Innate Pharma shares are owned by company insiders. Comparatively, 0.0% of Aditxt shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Innate Pharma and Aditxt’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Aditxt	-1,217,927.00%	-374.60%	-92.82%

Summary

Innate Pharma beats Aditxt on 5 of the 9 factors compared between the two stocks.

About Innate Pharma

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

About Aditxt

Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.